This article by Louis O Neill was originally published on The Green Fund, and appears here with permission.
2020 was a year unlike any other, and this goes for the cannabis industry as well. So how did cannabis fare last year?
When the coronavirus hit, the world was brought to a screeching halt as citizens across the globe were told to shut their stores and stay indoors. The lockdowns resulted in a huge spike in unemployment and business closures, in addition to the growing number of cases and deaths from COVID-19.
Needless to say, 2020 was a tumultuous year for nearly every individual and industry imaginable. In light of this, however, the cannabis industry managed to secure some real triumphs in the face of adversity and continued to progress in many respects.
Australian managing partner of McKinsey regrets consultancy s role during opioid epidemic
MonMonday 21
updated
TueTuesday 22
Purdue Pharma has made billions selling the prescription painkiller OxyContin.
(
Print text only
Cancel
A damaging exposé has revealed how international consulting firm McKinsey & Company tried to pump up sales of an addictive painkiller during the opioid epidemic.
Key points:
Consultancy firm McKinsey advised Purdue Pharma on how to increase the market share of its painkiller, OxyContin, at the height of the opioid crisis
Its advice included offering rebates for OxyContin overdoses
A McKinsey Australia spokesperson acknowledged a Zoom meeting was held after the revelations, saying it was part of a commitment to consider broader societal impacts of the firm s work